By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lundbeck Inc. 

Four Parkway North
Suite 200
Deerfield  Illinois  60015  U.S.A.
Phone: 800-455-1141 Fax: 847-282-1001

Lundbeck Inc. - Making a Difference One Patient at a Time

Headquartered in Deerfield, Illinois, with a portfolio of 17 specialty therapies and a pipeline of promising central nervous system (CNS) drugs, Lundbeck Inc. is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders and rare diseases for which few, if any, effective treatments are available.

As a wholly-owned subsidiary of H. Lundbeck A/S of Denmark, Lundbeck Inc. has a unique ownership structure. The company is 70 percent owned by the Lundbeck Foundation, which contributes millions annually to scientific research. In 2009, the Foundation granted more than $58 million to support research in biomedical and natural sciences.

Lundbeck Inc. offers the chance to make a difference while working in a unique and innovative environment. We are united by our passion and responsibility for helping the people with unmet medical needs. In addition to our extensive CNS pipeline that addresses a range of disorders from Alzheimer’s disease to Parkinson’s disease and depression, Lundbeck focuses on rare diseases with five orphan-designated therapies on the market and one more in late-stage development.

Our team of 350 pharmaceutical professionals, including an experienced team of clinical, regulatory and commercial experts, has a proven track record of working effectively with the U.S. Food and Drug Administration, developing and marketing high-need drugs that improve patients’ lives, and quickly and cost effectively bringing new products to market. Our operational excellence, diverse commercial portfolio and compelling development pipeline puts us in an excellent position for continued innovation and growth that will benefit patients for years to come.

At Lundbeck you can make a difference one patient at a time. If you wish to join a team where the challenges are great, the mission is meaningful and you can directly see the results of your hard work, Lundbeck may be the place for you.

Key Statistics

Ownership: Public

Web Site: Lundbeck
Symbol: LUN.CO

Company News
Lundbeck (LUN.CO) Reports 13% Revenue Growth And A Doubling Of EBIT In First Half Of 2017 8/9/2017 1:18:26 PM
Lundbeck (LUN.CO) Collaborates On Large First-Of-Its Kind Study Of Links Between Genetics And Psychiatric Disorders 8/2/2017 10:34:24 AM
Mixed Data For Alzheimer’s-Type Dementia Drug Leave Lundbeck (LUN.CO), Otsuka Pharma Investors Unsettled 5/2/2017 6:52:45 AM
Otsuka Pharma And Lundbeck (LUN.CO) Announce Results Of Brexpiprazole On Symptoms Of Agitation Related To Alzheimer’s-Type Dementia 5/2/2017 6:52:20 AM
Health Canada Approves Otsuka Pharma And Lundbeck (LUN.CO)'s REXULTI (Brexpiprazole) As A Treatment For Schizophrenia In Adults 2/20/2017 6:37:22 AM
Circuit Therapeutics Announces Research Collaboration With Lundbeck Inc. (LUN.CO) 12/19/2016 12:26:33 PM
Citizens United For Research In Epilepsy (CURE) And Lundbeck Inc. (LUN.CO) Announce National Launch Of Education Enrichment Fund 12/2/2016 7:47:00 AM
Citizens United For Research In Epilepsy (CURE) And Lundbeck Inc. (LUN.CO) Announce National Launch Of Education Enrichment Fund 12/2/2016 7:33:35 AM
Lundbeck Inc. (LUN.CO) Release: Post-Hoc Analysis Of Open-Label Extension Study Assesses The Use Of ONFI (Clobazam) CIV And The Potential For Tolerance 9/29/2016 10:43:27 AM
Lundbeck Inc. (LUN.CO) Release: FDA Approves Changes To The SABRIL (vigabatrin) REMS Program 6/24/2016 10:54:23 AM